About Us   |   Contact Us          
HOME REPORTS TRACK RECORD DISCLAIMER
  


   REPORTS

 MAY2016 
23
Stock: CLRB  Our Opinion: SHORT
HEADLINE: Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO


 MAR2016 
29
Stock: KERX  Our Opinion: SHORT
HEADLINE: Keryx Biopharmaceuticals Announces Positive Top-line Results from Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Adults with Non-Dialysis Dependent Chronic Kidney Disease


Hammer Research

About Us
Contact Us
Subscribe
Disclaimer
Site

Home
Reports
Track Record
Follow Us

Copyright 2017 Hammer Research Corporation. All rights reserved.